Themis Bioscience GmbH

📍 Vienna, Austria🗓 Founded 2009👥 40 employees💰 Last funded Nov 2019
Biotechnology🌐 themisbio.com
Website LinkedIn
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.
4
Total investors
1
Early stage
0
Mid stage
2
Late stage
2009
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
2
Austria
1
Investor activity2009–2019 · investors recorded per year
20091201612017120191
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Themis Bioscience GmbH?
Themis Bioscience GmbH has 4 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did Themis Bioscience GmbH last raise funding?
The most recent investment in Themis Bioscience GmbH recorded on gritt.io was in November 2019.
When was Themis Bioscience GmbH founded?
Themis Bioscience GmbH was founded in 2009.
What industry is Themis Bioscience GmbH in?
Themis Bioscience GmbH operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Themis Bioscience GmbH based?
Themis Bioscience GmbH is headquartered in Vienna, Austria.